WB, IP, IF-F, IF-IC, FC-FP, FC-L
M
Endogenous
20-30
Rabbit IgG
#Q9ET35
57916
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:100 |
| Immunofluorescence (Frozen) | 1:50 - 1:100 |
| Immunofluorescence (Immunocytochemistry) | 1:50 - 1:100 |
| Flow Cytometry (Fixed/Permeabilized) | 1:50 - 1:200 |
| Flow Cytometry (Live) | 1:50 - 1:200 |
Storage
Specificity / Sensitivity
Species Reactivity:
Mouse
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of mouse TACI/TNFRSF13B/CD267 protein.
Background
Transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI), also known as tumor necrosis factor receptor superfamily member 13B (TNFRSF13B) and cluster of differentiation 267 (CD267), is a single-pass type III membrane receptor that is highly expressed on the surface of mature innate-like B cells, such as marginal zone and B-1 B cells in mice, and memory B cells in humans (1-3). TACI/TNFRSF13B/CD267 is also expressed on the surface of activated T cells (4), while monocytes and dendritic cells express lower levels of TACI/TNFRSF13B/CD267 primarily intracellularly (5,6). TACI/TNFRSF13B/CD267 is the receptor for soluble ligands BAFF/TNFSF13B and APRIL/TNFSF13 (7,8). Upon ligation, TACI/TNFRSF13B/CD267 recruits tumor necrosis factor receptor–associated factor (TRAF) family members and calcium signal-modulating cyclophilin ligand (CAMLG) in order to activate NFAT, NF-κB, and AP-1 transcriptional programs (9-11). TACI/TNFRSF13B/CD267 is necessary for T cell-independent type II and type I responses (1,12), negative regulation of B cell and T follicular helper cell numbers (13,14), and promotion of class switch recombination in B cells (15). Mutations and aberrant regulation of TACI/TNFRSF13B/CD267 has been associated with cancer, autoimmune diseases, and immunodeficiency disorders (16-18). Multiple isoforms produced by alternative splicing have been identified.
- von Bülow, G.U. et al. (2000) Mamm Genome 11, 628-32.
- Mantchev, G.T. et al. (2007) J Immunol 179, 2282-8.
- Tsuji, S. et al. (2011) Blood 118, 5832-9.
- Wang, H. et al. (2001) Nat Immunol 2, 632-7.
- Chang, S.K. et al. (2006) Blood 108, 2687-94.
- Chang, S.K. et al. (2008) J Immunol 180, 7394-403.
- Wu, Y. et al. (2000) J Biol Chem 275, 35478-85.
- Yu, G. et al. (2000) Nat Immunol 1, 252-6.
- Hymowitz, S.G. et al. (2005) J Biol Chem 280, 7218-27.
- Xia, X.Z. et al. (2000) J Exp Med 192, 137-43.
- von Bülow, G.U. and Bram, R.J. (1997) Science 278, 138-41.
- Ozcan, E. et al. (2009) J Allergy Clin Immunol 123, 1277-86.e5.
- Seshasayee, D. et al. (2003) Immunity 18, 279-88.
- Ou, X. et al. (2012) Proc Natl Acad Sci U S A 109, 15401-6.
- He, B. et al. (2010) Nat Immunol 11, 836-45.
- Castigli, E. et al. (2005) Nat Genet 37, 829-34.
- Moura, R.A. et al. (2013) J Rheumatol 40, 1293-302.
- Abo-Elfadl, M.T. et al. (2020) Cytokine 125, 154790.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation IF-F: Immunofluorescence (Frozen) IF-IC: Immunofluorescence (Immunocytochemistry) FC-FP: Flow Cytometry (Fixed/Permeabilized) FC-L: Flow Cytometry (Live)
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.